|
Other issues |
Leading articles
Evidence and more evidence
PJ 2010;284:276
Swings and roundabouts
PJ 2010;284:276
News feature
How do we measure patient outcomes?
PJ 2010;284:283
Products
Product news
PJ 2010;284:284
Drug tariff updates | March 2010 prescriptions
PJ 2010;284:284
Updated DRUG ALERT: Glibenclamide tablets 5mg
PJ 2010;284:284
EpiPen
PJ 2010;284:284
Imuran and Lanoxin
PJ 2010;284:284
Pfizer’s Wyeth products
PJ 2010;284:284
Student bursaries
PJ 2010;284:284
Community survey
PJ 2010;284:284
EPS Release 2
PJ 2010;284:284
Healthcare politics website
PJ 2010;284:284
Broad spectrum
Patient-focused service development starts with pharmacists, not systems
PJ 2010;284:285
Letters
Letters for 20 March
PJ 2010;284:286-288
Interview
Paul Maltby
Extraordinary pharmacy: specialising in the field of radiopharmaceuticals
PJ 2010;284:289-290
Articles
What are the benefits for pharmacists of engaging in practice research?
PJ 2010;284:291-292
How sumatriptan transformed the lives of millions of migraine sufferers
PJ 2010;284:294-295
General Pharmaceutical Council Q&A
PJ 2010;284:297
Learning and development
Asking the pharmacist — questions from practice
Pityriasis versicolour
PJ 2010;284:293
My career
My work as an industrial pharmacist
PJ 2010;284:296
Prospector
Meet the Gömböcs: Weebles for adults
PJ 2010;284:298
Saint Cuthbert the wonder worker
PJ 2010;284:298
A newcomer to the periodic table
PJ 2010;284:298
